Translational center for kidney microphysiological systems to improve drug safety and efficacy
Active Cooperative Agreement Awarded Last action
- Award ID
- U2CTR004867
- Recipient
-
Icahn School Of Medicine At Mount Sinai UEI C8H9CNG1VBD9
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,930,256
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date 55% complete
- Place of performance
- New York, NY 10029, USA
Award details come from USAspending.gov.
Description
- Abstract
- Overall the overall goal of the university of washington translational center for kidney microphysiological systems to improve drug safety and efficacy is to expand upon kidney tissue chip developmental work our team has accomplished over the past decade, in order to qualify these microphysiological systems as drug development tools for specific contexts of use. Despite marked recent advances in our understanding of the physiology and pathophysiology of the human kidney in health and in disease, there are relatively few drugs that are proven to be safe and effective therapies for kidney diseases. Historically, the structural, functional and physiological complexity of the kidney has contributed significantly to the high rate of failures in therapeutic drug development. The complex multicellular architecture and unusual triad of physiological processes characterized by glomerular filtration, tubular secretion and tubular reabsorption, have limited the ability of animal models to recapitulate the diversity of etiologies, mechanisms, and heterogeneous clinical manifestations of most human kidney diseases. The limitations resulting from extrapolating animal model data to human kidney diseases constitutes a major barrier to developing new therapies. Until recently there has been a lack of human in vitro models that recapitulate critical aspects of kidney function or assess reparative mechanisms in response to injury. This is in part because microfluidic flow is so essential to kidney structure and cellular function. In response to this critical unmet need, our group has pioneered the development of 'human kidney-on-a-chip' microphysiological systems. Our in vitro on chip models recapitulate critical aspects of kidney physiology, assess the mechanisms and response to injury, and can test reparative mechanisms, all of which can substantially enhance successful drug development that is needed to improve the lives of people living with kidney diseases
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,614,842 | |
| Amendment | $161,282 | |
| Amendment | $161,282 | |
| Amendment | $1,451,541 | |
| Amendment | $1,451,541 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,522,442 | |
| Amendment | $1,522,442 | |
| Amendment | $1,522,442 | |
| Amendment | -$1,522,442 | |
| Amendment | -$1,522,442 | |
| Amendment | -$1,522,442 | |
| Amendment | $1,522,442 | |
| Amendment | $1,522,442 | |
| Amendment | $1,522,442 | |
| Original award | $1,522,442 |
Show all 19
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Plurexa LLC | $258,550 | |
| University Of Washington | $2,718,444 |
Quick answers
Who received award U2CTR004867?
U2CTR004867 was awarded to Icahn School Of Medicine At Mount Sinai by National Center for Advancing Translational Sciences (National Institutes of Health) on February 1, 2024.
How much is award U2CTR004867 worth?
$10,930,256 has been obligated on U2CTR004867.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award